Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis
…, E Rüther, O Sabri, P Sanchez-Juan, I Santana… - Jama, 2015 - jamanetwork.com
Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …
Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease
…, MR Simões, L Alves, I Santana - Alzheimer Disease & …, 2013 - journals.lww.com
The Montreal Cognitive Assessment (MoCA) was recently proposed as a cognitive screening
test for milder forms of cognitive impairment, having surpassed the well-known limitations …
test for milder forms of cognitive impairment, having surpassed the well-known limitations …
A Pan‐European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Genomic Instability, and Intermediate Repeats
…, I Piaceri, I Santana, B Santiago, I Santana… - Human …, 2013 - Wiley Online Library
We assessed the geographical distribution of C9orf72 G 4 C 2 expansions in a pan‐ E
uropean frontotemporal lobar degeneration ( FTLD ) cohort (n = 1,205), ascertained by the E …
uropean frontotemporal lobar degeneration ( FTLD ) cohort (n = 1,205), ascertained by the E …
Montreal Cognitive Assessment (MoCA): normative study for the Portuguese population
…, MR Simões, L Alves, I Santana - Journal of clinical and …, 2011 - Taylor & Francis
The Montreal Cognitive Assessment (MoCA) is a brief cognitive screening instrument with
good psychometric features and an excellent sensitivity in the early detection of mild cognitive …
good psychometric features and an excellent sensitivity in the early detection of mild cognitive …
[HTML][HTML] Data mining methods in the prediction of Dementia: A real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic …
…, D Silva, A Rodrigues, M Guerreiro, I Santana… - BMC research …, 2011 - Springer
Background Dementia and cognitive impairment associated with aging are a major medical
and social concern. Neuropsychological testing is a key element in the diagnostic …
and social concern. Neuropsychological testing is a key element in the diagnostic …
[HTML][HTML] Pathophysiology of blood–brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and …
…, G Santo, F Silva, L Ferreira, I Santana… - Frontiers in …, 2020 - frontiersin.org
The blood–brain barrier (BBB) is a dynamic interface responsible for maintaining the central
nervous system homeostasis. Its unique characteristics allow protecting the brain from …
nervous system homeostasis. Its unique characteristics allow protecting the brain from …
Mitochondria dysfunction of Alzheimer's disease cybrids enhances Aβ toxicity
SM Cardoso, I Santana, RH Swerdlow… - Journal of …, 2004 - Wiley Online Library
Alzheimer's disease (AD) brain reveals high rates of oxygen consumption and oxidative
stress, altered antioxidant defences, increased oxidized polyunsaturated fatty acids, and …
stress, altered antioxidant defences, increased oxidized polyunsaturated fatty acids, and …
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage
…, A Nordlund, A De Mendonça, D Silva, I Santana… - Brain, 2015 - academic.oup.com
Three sets of research criteria are available for diagnosis of Alzheimer’s disease in subjects
with mild cognitive impairment: the International Working Group-1, International Working …
with mild cognitive impairment: the International Working Group-1, International Working …
Cytochrome c oxidase is decreased in Alzheimer's disease platelets
SM Cardoso, MT Proença, S Santos, I Santana… - Neurobiology of …, 2004 - Elsevier
Cytochrome c oxidase (COX) activity reportedly is reduced in Alzheimer’s disease (AD) brain
and platelets. The reasons for the defect in either tissue are unknown, but its presence in a …
and platelets. The reasons for the defect in either tissue are unknown, but its presence in a …
Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP
…, A Sa, L Samaranch, R Sánchez-Valle, I Santana… - Neurobiology of …, 2010 - Elsevier
Mutations in three genes (PSEN1, PSEN2, and APP) have been identified in patients with
early-onset (<65years) Alzheimer's disease (AD). We performed a screening for mutations in …
early-onset (<65years) Alzheimer's disease (AD). We performed a screening for mutations in …